louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00686504: Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
Official title: An Open Label, Non-randomized Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 After Oral Administration to Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Pain
PET
Phase 1
Analgesia
Positron Emission Tomography
mGlu5 receptor
Dose finding
Analgesia/Pain
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-05-29
Enrollment: 6
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The study is carried out in order to determine the relationship between AZD2066 exposure and mGluR5 receptor occupancy in the brain and to demonstrate that AZD2066 can displace \[11C\]AZ12713580 from mGluR5 binding-sites in the Central Nervous System


Eligibility criteria: Inclusion Criteria:

* Provision of informed consent
* BMI (Body Mass Index) of ≥19 to ≤28 kg/m2 and weight of ≥50 to ≤100 kg
* Normal MRI (Magnetic Resonance Imaging) scan at visit 2

Exclusion Criteria:

* History of previous or ongoing psychiatric disease or condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders
* History of psychotic disorder among first degree relatives (parents, siblings)
* History of use of antipsychotic, antidepressant or anxiolytic (anxiety treatment) drugs, prescribed or non-prescribed use. History of antidepressants or anxiolytics for non-psychiatric conditions such as pain or post-operative insomnia is allowed

Primary outcomes:
measure: Positron emission tomography using the radioligand radioligand [11C]AZ12713580
timeFrame: 4 times
Secondary outcomes:
measure: To investigate the safety and tolerability of AZD2066 by assessment of Adverse Events (AEs), vital signs measurements (blood pressure and pulse), electrocardiogram (ECG), physical examination, clinical chemistry, haematology and urinalysis.
timeFrame: 7 visits with tests for all subjects. Some tests will be done several times per visit. All tests will not be performed at every visit.
measure: To investigate pharmacokinetics of AZD2066
timeFrame: 15 times per subject. Up to 48 hours each time
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Research Site
Study officials:
affiliation: Astrazeneca Clinical Pharmacology Unit, Stockholm, Sweden
name: Bo Fransson
role: PRINCIPAL_INVESTIGATOR
affiliation: AstraZeneca R&D, Study Delivery, Clinical Development, Södertälje, Sweden
name: Sophia Bengtsson
role: STUDY_DIRECTOR
References:
Clinical trial NCT05005104: Causes of Complicated Appendicitis at Referral Hospital
Official title: Predictors of Complicated Appendicitis Among Patients Presented to Public Referral Hospitals in Harari Region: A Case-control Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Complicated Appendicitis
Keywords: complicated appendicitis, acute abdomen
Lead sponsor: Haramaya Unversity
Sponsor class: OTHER
First posted: 2021-08-13
Enrollment: 402
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: all patients with a diagnosis of acute appendicitis and admitted to a public hospital in Harari regional state.

Brief summary: The study was conducted on a medical record of previously treated patients for acute appendicitis at HFSUH, Harar, Ethiopia. The study design was case-control with a total sample size of 402.

Detailed description: The case-control study conducted at HFSUH was proceeded following the university's protocol and after passing institutional ethical review permission.

Eligibility criteria: Inclusion Criteria:

* patients diagnosed with acute appendicitis

Exclusion Criteria:

* incidental appendectomy patients

Primary outcomes:
measure: Number of patients having the predictors of complicated appendicitis.
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Harar
country: Ethiopia
facility: CHMS
state: Harari NS
Study officials:
affiliation: HU
name: Badhaasaa Bayissa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04431804: THYME AND CARVACROLL Nanoparticle Effect on Fungi
Official title: Effect of Thyme and Carvacroll Nanoparticles on Aspergillus Fumigatus Isolate From Intensive Care Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aspergillosis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-06-16
Enrollment: 210
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: intensive care patients

Brief summary: Invasive Aspergillosis (IA) has increasingly been recognized as an emerging disease of non-neutropenic patients and in patients admitted to the ICU, even in the absence of an apparent predisposing immune-deficiency, with incidence ranges from 0.3% to 5.8% with an overall mortality rate exceeding 80%.


Eligibility criteria: Inclusion Criteria:

* intensive care patients

Exclusion Criteria:

* none

Primary outcomes:
measure: fungicidal effect of silver nanoparticles on aspergillus fumigatus
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut university
Study officials:
References:
Clinical trial NCT05955404: Kangroo Mother Care
Official title: Effect of Kangaroo Mother Care in Alleviating Preterm Infant's Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Preterm Birth Complication
Lead sponsor: University of Baghdad
Sponsor class: OTHER
First posted: 2023-07-21
Enrollment: 21
Sex: ALL
Minimum age (years): 32
Maximum age (years): 37
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
Primary purpose: SUPPORTIVE_CARE

Brief summary: infants had a condition that might influence their responses to pain, e.g., congenital anomalies or severe illnesses requiring treatment with antiepileptics, muscle relaxants, or analgesic drugs.

Detailed description: infants had a condition that might influence their responses to pain, e.g., congenital anomalies or severe illnesses requiring treatment with antiepileptics, muscle relaxants, or analgesic drugs and comparing the pain intensity with preterm infants who receive conventional care.

Eligibility criteria: Inclusion Criteria:

* Preterm infants whose corrected gestational age from (32 - \<37) weeks of pregnancy
* Preterm infants who do not experience any painful procedure for last 24 hours
* Preterm infants do not receive any sedation for last 24 hours

Exclusion Criteria:

* full-term infants whose corrected gestational age is \>37 weeks
* extremely preterm (\< 28 weeks)
* very preterm (28-\<32 weeks)
* proven or suspected sepsis
* major congenital malformations
* all heart defect except neonatal Patent ductus arteriosus (PDA)
* necrotizing enterocolitis
* neurodevelopmental disability
* who receive respiratory support {Mechanical Ventilation, Continuous Positive Airway Pressure, or high-flow support
* indicated for surgery
* contraindication to oral sucrose
* Twins
* infants had a condition that might influence their responses to pain, e.g., congenital anomalies or severe illnesses requiring treatment with antiepileptics, muscle relaxants, or analgesic drugs

Primary outcomes:
measure: Premature Infant Pain Profile-Revised (PIPP-R)
timeFrame: Two months
Secondary outcomes:
Other outcomes:
Locations:
city: Baghdad
country: Iraq
facility: College of Nursing- The University of Baghdad
Study officials:
References:
Clinical trial NCT04556604: Surgical Consent During the COVID-19 Pandemic
Official title: Consent for Surgery During the COVID-19 Pandemic
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Consent
Lead sponsor: Medway Primary Care Trust
Sponsor class: OTHER_GOV
First posted: 2020-09-21
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adults presenting with general surgical, vascular or breast surgical issues that require surgical intervention

Brief summary: Multiloop audit of consenting practice in surgical procedures during the COVID-19 pandemic


Eligibility criteria: Exclusion Criteria:

* Children (under 18 years old)
* Participants who lack capacity and therefore cannot be consented appropriately

Primary outcomes:
measure: Compliance to consenting practice
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Gillingham
country: United Kingdom
facility: Medway NHS Foundation Trust
Study officials:
References:
Clinical trial NCT02028104: Stem Cell Therapy in Traumatic Brain Injury
Official title: Open Label Study of Autologous Bone Marrow Mononuclear Cells in Traumatic Brain Injury
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Traumatic Brain Injury
Lead sponsor: Neurogen Brain and Spine Institute
Sponsor class: OTHER
First posted: 2014-01-06
Enrollment: 0
Sex: ALL
Minimum age (years): 6
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to study the effect of stem cell therapy on common symptoms in patients with Traumatic Brain Injury


Eligibility criteria: Inclusion Criteria:

* Diagnosed cases of chronic traumatic brain injury
* Age above 6 months

Exclusion Criteria:

* presence of acute infections such as Human immunodeficiency virus/Hepatitis B - Virus/Hepatitis C Virus
* malignancies
* bleeding tendencies
* pneumonia
* renal failure
* severe liver dysfunction
* severe anemia \[Hemoglobin \< 8\]
* any bone marrow disorder
* space occupying lesion in brain
* other acute medical conditions such as respiratory infection and pyrexia
* pregnancy
* lactation

Primary outcomes:
measure: Change in clinical symptoms of traumatic brain injury
timeFrame: 6 months
Secondary outcomes:
measure: Disability Rating scale
timeFrame: 6 months
Other outcomes:
measure: SF-8 scale
timeFrame: 6 months
Locations:
city: Mumbai
country: India
facility: Neurogen brain and spine institute
state: Maharashtra
Study officials:
affiliation: Neurogen Brain and Spine Institute
name: Alok K Sharma, M.S., M.Ch
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lee DH, Lee JY, Oh BM, Phi JH, Kim SK, Bang MS, Kim SU, Wang KC. Functional recovery after injury of motor cortex in rats: effects of rehabilitation and stem cell transplantation in a traumatic brain injury model of cortical resection. Childs Nerv Syst. 2013 Mar;29(3):403-11. doi: 10.1007/s00381-012-1969-4. Epub 2012 Nov 24.
citation: Tian C, Wang X, Wang X, Wang L, Wang X, Wu S, Wan Z. Autologous bone marrow mesenchymal stem cell therapy in the subacute stage of traumatic brain injury by lumbar puncture. Exp Clin Transplant. 2013 Apr;11(2):176-81. doi: 10.6002/ect.2012.0053. Epub 2012 Aug 11.
Clinical trial NCT06923904: Potassium Nitrate Gel and Diode Laser in the Treatment of Dentinal Hypersensitivity
Official title: Potassium Nitrate Gel and Diode Laser in the Treatment of Dentinal Hypersensitivity
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Dentistry
Desensitization
Keywords: desensitizing treatment
diode laser
oral hygiene
dental sensitivity
Lead sponsor: University of Pavia
Sponsor class: OTHER
First posted: 2025-04-11
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This will be a randomized clinical trial (RCT) with a split-mouth design
Primary purpose: SUPPORTIVE_CARE

Brief summary: Our aim will be to evaluate the actual efficacy of diode lasers in laser desensitization by comparing the topical gel Emoform Actisens, containing 5% potassium nitrate, alone and in combination with a diode laser. Dental hypersensitivity (DH) will be assessed pre- (T0) and post-treatment (T1) and at 1 month (T2), 3 months (T3), and 6 months (T4).

Detailed description: This will be a randomized clinical trial (RCT) with a split-mouth design, involving 12 subjects, with two parallel groups. The dental elements will be divided into the Trial group, treated with a 980 nm diode laser and desensitizing topical gel, and the Control group, treated only with the same gel. DH will be assessed using the Shiff Air Index (SAI) and Visual Analog Scale (VAS).

Eligibility criteria: The inclusion criteria will be as follows: (a) a good standard of home oral hygiene and (b) at least two teeth affected by DH.

The exclusion criteria will be: (a) individuals taking pain relievers; (b) individuals undergoing orthodontic treatment; (c) non-vital teeth; (d) teeth with restorative materials; and (e) pregnant or breastfeeding women

Primary outcomes:
measure: degree of dentin hypersensitivity
timeFrame: From enrollment to 6 months after desensitizing procedure
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01310504: The Use of the FAST (Focused Abdominal Scan for Trauma) Scan by Paramedics in Mass Casualty Incidents
Official title: The Use of the FAST Scan by Paramedics in Mass Casualty Incidents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mass Casualty
Lead sponsor: Ascension Health
Sponsor class: INDUSTRY
First posted: 2011-03-08
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Initially a group of paramedics will be trained to perform FAST (Focused Abdominal Scan for Trauma) scans. The paramedics will then enter a simulated mass causality incident and triage patients. Volunteers in the study will include peritoneal dialysis patients ("non stable") and non-peritoneal dialysis patients ("stable"). They will use the ultrasound to perform FAST scans on the patients to determine which subjects are "stable" and which are "unstable" patients. They will record which patients they consider need transport first. This data will be used to evaluate accuracy and speed of the FAST scan. When the paramedic identifies free fluid within the volunteer, they will be able to make the decision to upgrade these patients and ultimately transport them more quickly. The paramedics will be evaluated for time and accuracy with the FAST scan.

Detailed description: Ultrasound and the FAST (Focused Abdominal Scan for Trauma) scan is currently being used in the Emergency Department to help evaluate trauma patients. In the field a paramedic will use the START (Simple Triage Rapid Treatment) triage procedure to evaluate many patients and to help decide which patients are more critical and therefore need to be transported first. This study aims to create a mass casualty environment through the use of 10 volunteers who are on peritoneal dialysis and 10 patients who are not.

Eligibility criteria: Inclusion Criteria:

Paramedic - at least one year in the field, physically able to perform the test

Patients:

* (10)peritoneal dialysis patient that are able to leave dialysate in abdominal cavity for the duration of the test
* (10) subjects not on peritoneal dialysis who are available for the duration of the test

Exclusion Criteria:

* Under 18 years of age

Primary outcomes:
measure: To evaluate the use of the ultra sound and FAST scans in a simulation of a mass causality incident by paramedics for accuracy and speed
timeFrame: up to 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Grand Blanc
country: United States
facility: Genesys Regional Medical Center
state: Michigan
Study officials:
affiliation: Ascension Health
name: James A Cusser, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03816501: Effect of Preoperative Music on Anxiety
Official title: The Effect of Favorite Music on Postoperative Anxiety and Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Music on Postoperative Anxiety
Keywords: postoperative anxiety
State - Trait Anxiety Inventory
Lead sponsor: Ankara Diskapi Training and Research Hospital
Sponsor class: OTHER
First posted: 2019-01-25
Enrollment: 117
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: In this study, we are planning to evaluate whether listening to the music of the patient's choice preoperatively contributes to postoperative anxiety.

Detailed description: Preoperative anxiety can be detected via structured and standardised screening by the State - Trait Anxiety Inventory (STAI) I and II.

117 patients scheduled for inguinal hernia surgery for any reason in the age range of 18-70 will be included in our study. preoperative STAI I and II score (anxiety questionnaire) will be applied to each patient. The patients will be divided into two groups as preoperative music played and not played. The list of patients listening to the music will be played through the headphones which are the preference of the patients. The postoperative STAI questionnaire will be applied again. results will be evaluated statistically

Eligibility criteria: Inclusion Criteria:

* inguinal hernia surgery
* speak Turkish language

Exclusion Criteria:

* Patients with dementia and psychiatric disorders
* anxiolytic and psychiatric drug users
* patients without written consent
* poor vision,
* significant hearing loss,
* active opioid use,
* unwillingness to participate in the study
* unwillingness to listening to music

Primary outcomes:
measure: STAI score
timeFrame: 24 hours
measure: 11-point numerical rating scale (NRS)
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Diskapi Teaching and Research Hospital
state: Altindag
Study officials:
References:
Clinical trial NCT02582801: Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer
Official title: 18F-Alfatide Ⅱ PET/CT in the Diagnosis and Treatment Response Evaluation of Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Breast Cancer
Keywords: PET/CT
Alfatide Ⅱ
breast cancer
Lead sponsor: Jinling Hospital, China
Sponsor class: OTHER
First posted: 2015-10-21
Enrollment: 46
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: 18F-Alfatide Ⅱ PET/CT in breast cancer patients

Detailed description: The investigators aim to assess the clinical application of 18F-Alfatide Ⅱ PET/CT in the diagnosis and treatment response monitoring of breast cancer.

Eligibility criteria: Inclusion Criteria:

* The patients have been suspected or diagnosed with breast cancer and they have not received any treatment; It must fulfill the ethical requirements and subjects have signed an informed consent.

Exclusion Criteria:

* Pregnancy or nursing mothers; Those patients accompanied by other serious diseases such as cardiac functional insufficiency, hepatic and renal function insufficiency.

Primary outcomes:
measure: Maximum standardized uptake value (SUVmax)
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Jinling Hospital
state: Jiangsu
Study officials:
affiliation: Jinling Hospital, China
name: Guangming Lu, Professor
role: STUDY_CHAIR
References:
citation: Yu C, Pan D, Mi B, Xu Y, Lang L, Niu G, Yang M, Wan W, Chen X. (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2021-8. doi: 10.1007/s00259-015-3118-2. Epub 2015 Jul 1.
citation: Wang SY, Bao X, Wang MW, Zhang YP, Zhang YJ, Zhang JP. Radiation dosimetry estimates of (18)F-alfatide II based on whole-body PET imaging of mice. Appl Radiat Isot. 2015 Nov;105:1-5. doi: 10.1016/j.apradiso.2015.07.013. Epub 2015 Jul 13.
citation: Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X. Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases. Theranostics. 2015 Jul 12;5(10):1115-21. doi: 10.7150/thno.12938. eCollection 2015.
citation: Wu C, Yue X, Lang L, Kiesewetter DO, Li F, Zhu Z, Niu G, Chen X. Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors. Theranostics. 2014 Feb 26;4(5):546-55. doi: 10.7150/thno.8159. eCollection 2014.
citation: Guo J, Guo N, Lang L, Kiesewetter DO, Xie Q, Li Q, Eden HS, Niu G, Chen X. (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy. J Nucl Med. 2014 Jan;55(1):154-60. doi: 10.2967/jnumed.113.122069. Epub 2013 Nov 14.
Clinical trial NCT01858701: Visual Performance Investigation of Two Toric Soft Contact Lenses
Official title: Visual Performance Investigation of Two Toric Soft Contact Lenses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Refractive Error
Astigmatism
Myopia
Hyperopia
Keywords: myopia
hyperopia
astigmatism
contact lenses
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2013-05-21
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the amount of coma as measured by aberrometry induced by two silicone hydrogel toric lenses in astigmatic participants.


Eligibility criteria: Inclusion Criteria:

* Sign informed consent;
* Wears toric soft contact lenses;
* Can be successfully fit with study lenses within the power ranges available;
* Has cylinder of ≥ -0.75 diopter in both eyes;
* Has correctable vision of at least 0.1 (logMAR) or better in each eye at distance with both study lenses;
* Willing and able to wear study lenses on a daily wear basis for at least 5 days a week, minimum 8 hours per day, and attend all study visits;
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Any ocular condition that would contraindicate contact lens wear;
* Use of medications for which contact lens wear could be contraindicated;
* Monocular (only 1 eye with functional vision) or fit with 1 lens;
* History of herpetic keratitis, ocular surgery, or irregular cornea;
* Known sensitivity to the diagnostic pharmaceuticals to be used in the study;
* Requires presbyopic correction;
* Use of rewetting/lubricating eye-drops more than twice a day;
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Mean Ocular Coma Score at 5mm Pupil at Day 30
timeFrame: Day 30
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Alcon Research
name: Jessie Lemp, MS
role: STUDY_DIRECTOR
affiliation: School of Optometry and Vision Science
name: Lyndon Jones, PhD
role: PRINCIPAL_INVESTIGATOR
References: